Ratio Therapeutics Inc., a pharmaceutical company developing radiopharmaceuticals for cancer treatment and monitoring, has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.     Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments of up to $745 million and is eligible to receive tiered royalty payments. Ratio will col...